albuminuria >300 mg/day
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
albuminuria >300 mg/day is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Type 2 Diabetes, Cardiovascular Disease, Kidney Disease. Explore the targeted therapies, indications, testing methods, and companies developing albuminuria >300 mg/day drugs below.
Search albuminuria >300 mg/day Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting albuminuria >300 mg/day
| Drug | Company | Therapeutic Area |
|---|---|---|
| INVOKAMET | Johnson & Johnson | Metabolic |